INmune Bio Study Links Traumatic Brain Injury to Alzheimer’s via TNF, XPro1595 Shows Promise
Event summary
- INmune Bio’s XPro1595 prevented brain-injury-induced Alzheimer’s pathology, memory loss, and pain in a peer-reviewed preclinical study published July 15, 2026.
- The study found that traumatic brain injury (TBI) raised levels of TNF and amyloid beta (Aβ42), key proteins linked to Alzheimer’s disease.
- XPro1595 treatment reduced TNF levels, prevented the rise in Aβ42, improved learning and memory, and reduced pain in 3xTg-AD mice.
- The research was funded by the Department of Defense and published in the Journal of Neurotrauma.
The big picture
This study reinforces the link between traumatic brain injury and Alzheimer’s disease, highlighting soluble TNF as a key biological driver. INmune Bio’s XPro1595 offers a targeted approach to interrupting this inflammatory cascade, positioning the company at the forefront of neuroinflammation research in neurodegenerative diseases. The findings could expand XPro1595’s potential applications beyond early Alzheimer’s to include TBI-related cognitive decline.
What we're watching
- Clinical Translation
- Whether XPro1595’s preclinical success in TBI-induced Alzheimer’s pathology will translate to human trials and regulatory approval.
- Market Positioning
- How INmune Bio positions XPro1595 against existing and emerging therapies targeting neuroinflammation in Alzheimer’s disease.
- Regulatory Pathway
- The pace at which INmune Bio advances XPro1595 through its Phase 2b/3 seamless adaptive registrational program for neuroinflammation-enriched early Alzheimer's disease.
Related topics